completed

The objective of the ACTIVE W study was to determine the efficacy (noninferiority) of clopidogrel plus ASA versus an other oral anticoagulation in patients with atrial fibrillation (AF) and at least one risk factor for stroke.

Composite outcome:

Stroke, non-CNS systemic embolism, myocardial infarction, or vascular death.

Study Type

Interventional - Drug

Study Design

Double-blind, placebo controlled non-inferiority RCT

NO. of Countries

33

NO. of Sites

633

NO. of Participants

6507

Study Period

2003 - 2005

Sponsor

Sanofi

Sanofi

Bristol-Myers Squibb

Back To Top